Treating Patients Beyond Borders - Antengene Successfully Hosted Its First R&D Day

- Highlighted R&D Strategy and Broad Pipeline of 15 Programs including 10 with Worldwide Rights - ATG-010's First Approval in Asia transforms Antengene into a Commercial Entity, 10 Studies in ATG-010 being Conducted in Mainland China - Exciting ATG-008 (mTORC1/2 inhibitor) Signal, ATG-017...